GILD · Gilead Sciences, Inc. · Webcasts, Transcripts & Audio

Earnings call

FY26 · Q3

2026-10-29

Gilead Sciences, Inc. (GILD) Q3 2026 Earnings Call

Scheduled

Results not yet reported

Audio Transcript Slides 8-K10-Q

Conference

Investor event

2026-09-15

Gilead Sciences, Inc. (GILD) September 15, 2026 Conference Transcript

No reported result — non-financial event

Audio Transcript Slides

Conference

Investor event

2026-09-09

Gilead Sciences, Inc. (GILD) September 9, 2026 Conference Transcript

No reported result — non-financial event

Audio Transcript Slides

Earnings call

FY26 · Q2

2026-08-04

Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call Transcript

Confident tone HIV portfolio performance HIV pipeline and weekly oral regimens Trodelvi oncology growth

Revenue

$7.80B

▲ 10.2% YoY

Diluted EPS

$-8.45

▼ 641.7% YoY

Gross margin

79.8%

Rev · 8q

Audio Transcript Slides 8-K10-Q

Conference

Investor event

2026-06-09

Gilead Sciences, Inc. (GILD) June 9, 2026 Conference Transcript

No reported result — non-financial event

Audio Transcript Slides

Conference

Investor event

2026-05-28

Gilead Sciences, Inc. (GILD) May 28, 2026 Conference Transcript

No reported result — non-financial event

Audio Transcript Slides

Conference

Investor event

2026-05-19

Gilead Sciences, Inc. (GILD) May 19, 2026 Conference Transcript

No reported result — non-financial event

Audio Transcript Slides

Conference

Investor event

2026-05-12

Gilead Sciences, Inc. (GILD) May 12, 2026 Conference Transcript

No reported result — non-financial event

Audio Transcript Slides

Earnings call

FY26 · Q1

2026-05-07

Gilead Sciences, Inc. (GILD) Q1 2026 Earnings Call Transcript

Confident tone HIV franchise growth and pipeline Cell therapy and anitocel launch Business development and acquisitions

Revenue

$6.96B

▲ 4.4% YoY

Diluted EPS

$1.61

▲ 54.8% YoY

Gross margin

79.2%

Rev · 8q

Audio Transcript Slides 8-K10-Q

Annual General Meeting

Investor event

2026-04-30

Gilead Sciences, Inc. (GILD) April 30, 2026 Annual General Meeting Transcript

No reported result — non-financial event

Audio Transcript Slides

Conference

Investor event

2026-03-11

Gilead Sciences, Inc. (GILD) March 11, 2026 Conference Transcript

No reported result — non-financial event

Audio Transcript Slides

Conference

Investor event

2026-03-10

Gilead Sciences, Inc. (GILD) March 10, 2026 Conference Transcript

No reported result — non-financial event

Audio Transcript Slides

Conference

Investor event

2026-03-03

Gilead Sciences, Inc. (GILD) March 3, 2026 Conference Transcript

No reported result — non-financial event

Audio Transcript Slides

Earnings call

FY25 · Q4

2026-02-10

Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Transcript

Confident tone HIV business growth and Biktarvy YES2GO HIV prevention launch Oncology and Trodelvy expansion

Revenue

$7.92B*

▲ 4.7% YoY

Gross margin

79.5%

Rev · 8q

Audio Transcript Slides 8-K10-K

Conference

Investor event

2026-01-12

Gilead Sciences, Inc. (GILD) January 12, 2026 Conference

No reported result — non-financial event

Audio Transcript Slides

Conference

Investor event

2025-11-19

Gilead Sciences, Inc. (GILD) November 19, 2025 Conference Transcript

No reported result — non-financial event

Audio Transcript Slides

Earnings call

FY25 · Q3

2025-10-30

Gilead Sciences, Inc. (GILD) Q3 2025 Earnings Call Transcript

Confident tone HIV franchise growth Yeztugo launch Oncology pipeline

Revenue

$7.77B

▲ 3% YoY

Diluted EPS

$2.43

▲ 143% YoY

Gross margin

79.8%

Rev · 8q

Audio Transcript Slides 8-K10-Q

Earnings call

FY25 · Q2

2025-08-07

Gilead Sciences, Inc. (GILD) Q2 2025 Earnings Call Transcript

Confident tone HIV franchise performance Yeztugo (lenacapavir) launch Trodelvy in metastatic TNBC

Revenue

$7.08B

▲ 1.8% YoY

Diluted EPS

$1.56

▲ 20.9% YoY

Gross margin

78.8%

Rev · 8q

Audio Transcript Slides 8-K10-Q

Earnings call

FY25 · Q1

2025-04-24

Gilead Sciences, Inc. (GILD) Q1 2025 Earnings Call Transcript

Confident tone HIV franchise and Biktarvy growth Lenacapavir for PrEP launch Trodelvy and oncology pipeline

Revenue

$6.67B

▼ 0.3% YoY

Diluted EPS

$1.04

Gross margin

76.9%

Rev · 8q

Audio Transcript Slides 8-K10-Q

Earnings call

FY24 · Q4

2025-02-11

Gilead Sciences, Inc. (GILD) Q4 2024 Earnings Call Transcript

Confident tone HIV franchise growth and leadership Lenacapavir for HIV prevention Pipeline depth and long-term growth outlook

Revenue

$7.57B*

▲ 6.4% YoY

Gross margin

79.1%

Rev · 8q

Audio Transcript Slides 8-K10-K

Earnings call

FY24 · Q3

2024-11-06

Gilead Sciences, Inc. (GILD) Q3 2024 Earnings Call Transcript

Confident tone Lenacapavir for HIV PrEP Oncology and cell therapy HIV franchise performance

Revenue

$7.54B

▲ 7% YoY

Diluted EPS

$1.00

▼ 42.2% YoY

Gross margin

79.1%

Rev · 8q

Audio Transcript Slides 8-K10-Q

Earnings call

FY24 · Q2

2024-08-08

Gilead Sciences, Inc. (GILD) Q2 2024 Earnings Call Transcript

Confident tone HIV prevention (lenacapavir / PURPOSE) Oncology - Trodelvy Long-acting HIV pipeline

Revenue

$6.95B

▲ 5.4% YoY

Diluted EPS

$1.29

▲ 55.4% YoY

Gross margin

77.8%

Rev · 8q

Audio Transcript Slides 8-K10-Q

Earnings call

FY24 · Q1

2024-04-25

Gilead Sciences, Inc. (GILD) Q1 2024 Earnings Call Transcript

Confident tone HIV franchise performance and growth Liver disease and Celadelpar Trodelvy and oncology

Revenue

$6.69B

▲ 5.3% YoY

Diluted EPS

$-3.34

▼ 517.5% YoY

Gross margin

76.8%

Rev · 8q

Audio Transcript Slides 8-K10-Q

Earnings call

FY23 · Q4

2024-02-06

Gilead Sciences, Inc. (GILD) Q4 2023 Earnings Call Transcript

Positive tone Oncology portfolio expansion Trodelvi EVOKE-01 trial outcome 2024 clinical catalysts and pipeline updates

Revenue

$7.11B*

▼ 3.7% YoY

Gross margin

70.6%

Rev · 8q

Audio Transcript Slides 8-K10-K

Earnings call

FY23 · Q3

2023-11-07

Gilead Sciences, Inc. (GILD) Q3 2023 Earnings Call Transcript

Revenue

$7.05B

▲ 0.1% YoY

Diluted EPS

$1.73

▲ 21.8% YoY

Gross margin

77.8%

Rev · 8q

Audio Transcript Slides 8-K10-Q

Earnings call

FY23 · Q2

2023-08-03

Gilead Sciences, Inc. (GILD) Q2 2023 Earnings Call Transcript

Revenue

$6.60B

▲ 5.4% YoY

Diluted EPS

$0.83

▼ 8.8% YoY

Gross margin

78.1%

Rev · 8q

Audio Transcript Slides 8-K10-Q

Earnings call

FY23 · Q1

2023-04-27

Gilead Sciences, Inc. (GILD) Q1 2023 Earnings Call Transcript

Revenue

$6.35B

▼ 3.6% YoY

Diluted EPS

$0.80

▲ 3900% YoY

Gross margin

77.9%

Rev · 8q

Audio Transcript Slides 8-K10-Q

Earnings call

FY22 · Q4

2023-02-02

Gilead Sciences, Inc. (GILD) Q4 2022 Earnings Call Transcript

Revenue

$7.39B*

▲ 2% YoY

Gross margin

81.1%

Rev · 8q

Audio Transcript Slides 8-K10-K

Earnings call

FY22 · Q3

2022-10-27

Gilead Sciences, Inc. (GILD) Q3 2022 Earnings Call Transcript

Revenue

$7.04B

▼ 5.1% YoY

Diluted EPS

$1.42

▼ 30.7% YoY

Gross margin

80.2%

Rev · 8q

Audio Transcript Slides 8-K10-Q

Earnings call

FY22 · Q2

2022-08-02

Gilead Sciences, Inc. (GILD) Q2 2022 Earnings Call Transcript

Revenue

$6.26B

▲ 0.7% YoY

Diluted EPS

$0.91

▼ 24.8% YoY

Gross margin

77.0%

Rev · 8q

Audio Transcript Slides 8-K10-Q

Earnings call

FY22 · Q1

2022-04-28

Gilead Sciences, Inc. (GILD) Q1 2022 Earnings Call Transcript

Revenue

$6.59B

▲ 2.6% YoY

Diluted EPS

$0.02

▼ 98.5% YoY

Gross margin

78.4%

Rev · 8q

Audio Transcript Slides 8-K10-Q

Earnings call

FY21 · Q4

2022-02-01

Gilead Sciences, Inc. (GILD) Q4 2021 Earnings Call Transcript

Revenue

$7.24B*

▼ 2.4% YoY

Gross margin

63.7%

Rev · 8q

Audio Transcript Slides 8-K10-K

Earnings call

FY21 · Q3

2021-10-28

Gilead Sciences, Inc. (GILD) Q3 2021 Earnings Call Transcript

Revenue

$7.42B

▲ 12.8% YoY

Diluted EPS

$2.05

▲ 606.9% YoY

Gross margin

83.5%

Rev · 8q

Audio Transcript Slides 8-K10-Q

Earnings call

FY21 · Q2

2021-07-29

Gilead Sciences, Inc. (GILD) Q2 2021 Earnings Call Transcript

Revenue

$6.22B

▲ 20.9% YoY

Diluted EPS

$1.21

Gross margin

77.6%

Rev · 8q

Audio Transcript Slides 8-K10-Q

Earnings call

FY21 · Q1

2021-04-29

Gilead Sciences, Inc. (GILD) Q1 2021 Earnings Call Transcript

Revenue

$6.42B

▲ 15.8% YoY

Diluted EPS

$1.37

▲ 12.3% YoY

Gross margin

78.8%

Rev · 8q

Audio Transcript Slides 8-K10-Q

Earnings call

FY20 · Q4

2021-02-04

Gilead Sciences, Inc. (GILD) Q4 2020 Earnings Call Transcript

Revenue

$7.42B

▲ 26.2% YoY

Diluted EPS

$1.23

▼ 42% YoY

Gross margin

79.9%

Rev · 8q

Audio Transcript Slides 8-K10-K

Earnings call

FY20 · Q3

2020-10-28

Gilead Sciences, Inc. (GILD) Q3 2020 Earnings Call Transcript

Revenue

$6.58B

▲ 17.4% YoY

Diluted EPS

$0.29

Gross margin

81.4%

Rev · 8q

Audio Transcript Slides 8-K10-Q

Earnings call

FY20 · Q2

2020-07-30

Gilead Sciences, Inc. (GILD) Q2 2020 Earnings Call Transcript

Revenue

$5.14B

▼ 9.5% YoY

Diluted EPS

$-2.66

▼ 281% YoY

Gross margin

77.8%

Rev · 8q

Audio Transcript Slides 8-K10-Q

Earnings call

FY20 · Q1

2020-04-30

Gilead Sciences, Inc. (GILD) Q1 2020 Earnings Call Transcript

Revenue

$5.55B

▲ 5.1% YoY

Diluted EPS

$1.22

▼ 20.8% YoY

Gross margin

81.1%

Rev · 8q

Audio Transcript Slides 8-K10-Q

Earnings call

FY19 · Q4

2020-02-04

Gilead Sciences, Inc. (GILD) Q4 2019 Earnings Call

Revenue

$5.88B

▲ 1.4% YoY

Diluted EPS

$2.12

Gross margin

70.0%

Rev · 8q

Audio Transcript Slides 8-K10-K